Synthetic Hydrogels as Carriers in Antisense Therapy: Preliminary Evaluation of an Oligodeoxynucleotide Covalent Conjugate with a Copolymer of 1-Vinyl-2-Pyrrolidinone and 2-Hydroxyethyl Methacrylate
Restricted accessResearch articleFirst published online April, 2001
Synthetic Hydrogels as Carriers in Antisense Therapy: Preliminary Evaluation of an Oligodeoxynucleotide Covalent Conjugate with a Copolymer of 1-Vinyl-2-Pyrrolidinone and 2-Hydroxyethyl Methacrylate
A major challenge of the antisense therapeutic strategies is the development of improved systems for the delivery of antisense oligodeoxynucleotides (AS ODNs) in order to enhance the cellular uptake, to assure a better efficiency in reaching the target tissue, and to provide sustained delivery over longer periods of time. Because the current methods for delivery (liposomes and cationic polymers) present somedisadvantages, the attention was directed toward the use of neutral polymers as carriers for the AS ODNs. Based on our previous work on synthetic hydrogels for vitreous substitution, we developed a poly[1-vinyl-2-pyrrolidinone-co-(2-hydroxyethyl methacrylate)] hydrogelas a potential carrier for AS ODNs. We have previously demonstrated that such hydrogels are not cytotoxic, and they may have growth-promoting effects on cultured fibroblasts. This copolymer also has the advantage of being injectable. In this study, a specific AS ODN was synthesized and then covalently bound to the copolymer via carbodiimide coupling method. The resulting conjugate was subjected to in vitro release experiments over 46 days in the presence of bovine vitreous humor. Compared with the control (no enzyme present), a significantamount of covalently bound ODN was released from the ODN-hydrogel conjugate, suggesting the possibility of using such systems for the sustained delivery of AS ODNs.
2. Capecchi, M. R.1989. “Altering the genome by homologous recombination”, Science, 244: 1288–1292.
3.
3. Schreier, H.1994. “The new frontier: Gene and oligonucleotide therapy”, Pharm. Acta Helv., 68: 145–159.
4.
4. Friedmann, T.1997. “Overcoming the obstacles to gene therapy”, Sci. Am., 276(6): 80–85.
5.
5. Yanez, R. J. and Porter, A. C. G.1998. “Therapeutic genetargeting”, Gene Ther., 5: 149–159.
6.
6. Gewirtz, A. M., Stein, C. A. and Glazer, P. M.1996. “Facilitating oligonucleotide delivery: Helping antisense deliver on its promise”, Proc. Natl. Acad. Sci. USA, 93: 3161–3163.
7.
7. Akhtar, S.1998. “Antisense technology: Selection and delivery of optimally acting antisense oligonucleotides”, J. Drug Targeting, 5: 225–234.
8.
8. Colman, A.1990. “Antisense strategies in cell and developmental biology”, J. Cell Sci., 97: 399–409.
9.
9. Uhlmann, E. and Peyman, A.1990. “Antisense oligonucleotides: A new therapeutic principle”, Chem. Rev., 90: 543–584.
10.
10. Cazenave, C. and Helene, C.1991. “Antisense oligonucleotides”, Antisense Nucleic Acids and Proteins. Fundamentals and Applications, J. N. M. Mol and A. R. van der Krol, eds. New York: Marcel Dekker, pp. 47–93.
11.
11. Crooke, S. T.1992. “Therapeutic applications of oligonucleotides”, Annual Rev. Pharmacol. Toxicol., 32: 329–376.
12.
12. Toulme, J. J.1992. “Artificial regulation of gene expression by complementary oligonucleotides—an overview”, Antisense RNA and DNA, J.A.H. Murray, ed. New York: Wiley-Liss, pp. 175–194.
13.
13. De Mesmaeker, A., Haner, R., Martin, P. and Moser, H. E.1995. “Antisense oligonucleotides”, Acc. Chem. Res., 28: 366–374.
14.
14. Crooke, S. T.1996. “Progress in antisense therapeutics”, Medicinal Res. Rev., 16: 319–344.
15.
15. Temsamani, J. and Guinot, P.1997. “Antisense oligonucleotides: A new therapeutic approach”, Biotechnol. Appl. Biochem., 26: 65–71.
16.
16. Juliano. R. L., Alahari, S., Yoo, H., Kole, R. and Cho, M.1999. “Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides”, Pharm. Res., 16: 494–502.
17.
17. Loke, S. L., Stein, C. A., Zhang, X. H., Mori, K., Nakanishi, M., Subasinghe, C., Cohen, J. S. and Neckers, L. M.1989. “Characterization of oligonucleotide transport into living cells”, Proc. Natl. Acad. Sci. USA, 86: 3474–3478.
18.
18. Bennett, R. M.1993. “As nature intended? The uptake of DNA and oligonucleotides by eukaryotic cells”, Antisense Res. Dev., 3: 235–241.
19.
19. Leonetti, J. P., Degols, G., Clarenc, J. P., Mechti, N. and Lebleu, B.1993. “Cell delivery and mechanisms of action of antisense oligonucleotides”, Prog. Nucleic Acid Res., 44: 143–166.
20.
20. Mahato, R. I., Takakura, Y. and Hashida, M.1997. “Development of targeted delivery systems for nucleic acid drugs”, J. Drug Targeting, 4: 337–357.
21.
21. Slepnev, V. I. and De Camilli, P.1998. “Endocytosis: an overview”, Self-Assembling Complexes for Gene Delivery, A.V. Kabanov, P. L. Felgner and L. W. Seymour, eds. Chichester: Wiley, pp. 71–88.
22.
22. Martiat, P., Lewalle, P., Taj, A. S., Philippe, M., Larondelle, Y., Vaerman, J. L., Wildmann, C., Goldman, J. M. and Michaux, J. L.1993. “Retrovirally transduced antisense sequences stably suppress P210 BCR-ABL expression and inhibit the proliferation of BCR/ABL-containing cell lines”, Blood, 81: 502–509.
23.
23. Clarenc, J. P., Degols, G., Leonetti, J. P., Milhaud, P. and Lebleu, B.1993. “Delivery of antisense oligonucleotides by poly(L-lysine) conjugation and liposome encapsulation”, Anti-Cancer Drug Design, 8: 81–94.
24.
24. Zelphati, O. and Szoka Jr., F. C.1996. “Liposomes as a carrier for intracellular delivery of antisense oligonucleotides: a realor magic bullet?”, J. Controlled Release, 41: 99–119.
25.
25. Juliano, R. L. and Akhtar, S.1992. “Liposomes as a drug delivery system for antisense oligonucleotides”, Antisense Res. Dev., 2: 165–176.
26.
26. Thierry, A. R. and Takle, G. B.1995. “Liposomes as a delivery system for antisense and ribozyme compounds”, Delivery Strategies for Antisense Oligonucleotide Therapeutics, S. Akhtar, Ed. Boca Raton, FL: CRC Press, pp. 199–221.
27.
27. Tari, A., Khodadadian, M., Ellerson, D., Deisseroth, A. and Lopez-Berestein, G.1996. “Liposomal delivery of oligonucleotides”, Leukemia Lymphoma, 21: 93–97.
28.
28. Bochot, A., Courvreur, P. and Fattal, E.2000. “Intravitreal administration of antisense oligonucleotides: Potential of liposomal delivery”, Prog. Retinal Eye Res., 19: 131–147.
29.
29. Leonetti, J. P., Degols, G. and Lebleu, B.1990. “Biological activity of oligonucleotide-poly(L-lysine) conjugates: mechanism of cell uptake”, Bioconjugate Chem., 1: 149–153.
30.
30. Boado, R. J.1995. “Antisense drug delivery through the blood-brain barrier”, Advanced Drug Del. Rev., 15: 73–107.
31.
31. Kabanov, A. V., Vinogradov, S. V., Suzdaltseva, Y. G. and Alakhov, V. Y.1995. “Water-soluble block polycations as carriers for oligonucleotide delivery”, Bioconjugate Chem., 6: 639–643.
32.
32. Kabanov, A. V., Szoka Jr., F. C. and Seymour, L. W.1998. “Interpolyelectrolyte complexes for gene delivery: polymer aspects of transfection activity”, Self-Assembling Complexes for Gene Delivery, A.V. Kabanov, P. L. Felgner and L. W. Seymour, eds. Chichester: Wiley, pp. 197–218.
33.
33. Seymour, L. W., Kataoka, K. and Kabanov, A. V.1998. “Cationic block copolymers as self-assembling vectors for gene delivery”, Self-Assembling Complexes for Gene Delivery, A. V. Kabanov, P. L. Felgner and L. W. Seymour, eds. Chichester: Wiley, pp. 220–239.
34.
34. Chavany, C., Doan, T. L., Couvreur, P., Puisieux, F. and Helene, C.1992. “Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides”, Pharm. Res., 9: 441–449.
35.
35. Chavany, C., Saison-Behmoaras, T., Doan, T. L., Puisieux, F., Couvreur, P. and Helene, C.1994. “Adsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake”, Pharm. Res., 11: 1370–1378.
36.
36. Schwab, G., Duroux, I., Chavany, C., Helene, C. and Saison-Behmoaras, E.1994. “An approach for new anticancer drugs: Oncogene-targeted antisense DNA”, Ann. Oncol., 5(Suppl. 4): 55–58.
37.
37. Lewis, K. J., Irwin, W. J. and Akhtar, S.1995. “Biodegradable poly(L-lactic acid) matrices for the sustained delivery of antisense oligonucleotides”, J. Controlled Release, 37: 173–183.
38.
38. Lewis, K. J., Irwin, W. J. and Akhtar, S.1998. “Development of a sustained-release biodegradable polymer delivery system for site-specific delivery of oligonucleotides: Characterization of P(LA-GA) copolymer microspheres in vitro”, J. Drug Targeting, 5: 291–302.
39.
39. Cleek, R. L., Rege, A. A., Denner, L. A., Eskin, S. G. and Mikos, A. G.1997. “Inhibition of smooth muscle cell growth in vitro by an antisense oligonucleotide released from poly(DL-lactic-co-glycolic acid) microparticles”, J. Biomed. Mater. Res., 35: 525–530.
40.
40. Yamakawa, I., Ishida, M., Kato, T., Ando, H. and Asakawa, N.1997. “Release behavior of poly(lactic acid-co-glycolic acid) implants containing phosphorothioate oligodeoxynucleotide”, Biol. Pharm. Bull., 20: 455–459.
41.
41. Edelman, E. R., Simons, M., Sirois, M. G. and Rosenberg, R. D.1995. “C-myc in vasculoproliferative disease”, Circulation Res., 76: 176–182.
42.
42. Bonora, G. M., Ivanova, E., Zarytova, V., Burcovich, B. and Veronese, F. M.1997. “Synthesis and characterization of high-molecular mass polyethylene glycol-conjugated oligonucleotides”, Bioconjugate Chem., 8: 793–797.
43.
43. Zhao, Q., Temsamani, J. and Agrawal, S.1995. “Use of cyclodextrin and its derivatives as carriers for oligonucleotide delivery”, Antisense Res. Dev., 5: 185–192.
44.
44. Abdou, S., Collomb, J., Sallas, F., Masura, A. and Finance, C.1997. “Beta-cyclodextrin derivatives as carriers to enhance theantiviral activity of an antisense oligonucleotide directed toward a coronavirus intergenic consensus sequence”, Arch. Virol., 142: 1585–1602.
45.
45. Dalton, P. D., Jefferson, A., Hong, Y., Chirila, T. V., Vijayasekaran, S. and Tahija, S. G.1995. “The use of Fourier transform infrared spectrometry for monitoring the retention of polymers in thevitreous humour”, Bio-Med. Mater. Eng., 5: 185–193.
46.
46. Dalton, P. D., Chirila, T. V., Hong, Y. and Jefferson, A.1995. “Oscillatory shear experiments as criteria for potential vitreous substitutes”, Polym. Gels Netw., 3: 429–444.
47.
47. Vijayasekaran, S., Chirila, T. V., Hong, Y., Tahija, S. G., Dalton, P. D., Constable, I. J. and McAllister, I. L.1996. “Poly(1-vinyl-2-pyrrolidinone) hydrogels as vitreous substitutes: Histopathological evaluation in the animal eye”, J. Biomater. Sci. Polym. Edn., 7: 685–696
48.
48. Hong, Y., Chirila, T. V., Vijayasekaran, S., Dalton, P. D., Tahija, S. G., Cuypers, M. J. H. and Constable, I. J.1996. “Crosslinked poly(1-vinyl-2-pyrrolidinone) as a vitreous substitute”, J. Biomed. Mater. Res., 30: 441–448.
49.
49. Chirila, T. V., Hong, Y. and Dalton, P. D.1996. “Artificial vitreous body”, Polymeric Materials Encyclopedia, J. C. Salamone, ed. Boca Raton, FL: CRC Press, pp. 1525–1531.
50.
50. Hong, Y., Chirila, T. V., Cuypers, M. J. H. and Constable, I. J.1996. “Polymers of 1-vinyl-2-pyrrolidinone as potential vitreous substitutes: physical selection”, J. Biomater. Appl., 11: 135–181.
51.
51. Hong, Y., Chirila, T. V., Vijayasekaran, S., Shen, W., Lou, X. and Dalton, P. D.1998. “Biodegradation in vitro and retention in the rabbit eye of crosslinked poly(1-vinyl-2-pyrrolidinone) hydrogel as a vitreous substitute”, J. Biomed. Mater. Res., 39: 650–659.
52.
52. Chirila, T. V. and Hong, Y.1998. “Poly(1-vinyl-2-pyrrolidinone hydrogels as vitreous substitutes: A rheological study”, Polym. Int., 46: 183–195.
53.
53. Chirila, T. V., Hong, Y., Dalton, P. D., Constable, I. J. and Refojo, M. F.1998. “The use of hydrophilic polymers as artificial vitreous”, Prog. Polym. Sci., 23: 475–508.
54.
54. Hong, Y., Chirila, T. V., Vijayasekaran, S., Davies, M. J. and Maley, M. A. L.1996. “In vitro cytotoxicity assay of synthetic hydrogels as potential vitreous substitutes”, In Vitro Toxicol., 9: 73–82.
55.
55. Hong, Y., Chirila, T. V., Fitton, J. H., Ziegelaar, B. W. and Constable, I. J.1997. “Effect of crosslinked poly(1-vinyl-pyrrolidinone) gels on cell growth in static cell cultures”, Bio-Med. Mater. Eng., 7: 35–47.
56.
56. Berman, E. R. and Voaden, M.1970. “The vitreous body”, Biochemistry of the Eye, C. N. Graymore, ed. London: Academic Press, pp. 405–462.
57.
57. Beaucage, S. L. and Radhakrishnan, P. I.1993. “The functionalization of oligonucleotides via phosphoramidite derivatives”, Tetrahedron, 49: 1925–1963.
58.
58. Taillandier, E. and Liquier, J.1992. “Infrared spectroscopy of DNA”, Methods Enzymol., 211: 307–335.
59.
59. Ivanovskaya, M. G., Gottikh, M. B. and Shabarova, Z. A.1987. “Modification of oligo(poly)nucleotide phosphomonoester groups in aqueous solutions”, Nucleosides Nucleotides, 6: 913–934.
60.
60. Shabarova, Z. A.1988. “Chemical development in the design of oligonucleotide probes for binding to DNA and RNA”, Biochimie, 70: 1323–1334.
